[Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis].
A 76 years-old male patient received mebendazole, 500 mg four times a day (appr. 29 mg per kg body weight) for treatment of sonographically and serologically proven cystic echinococcosis of the liver. On day 49 of this therapy he developed an exanthema, and mebendazole-administration was interrupted. At the same time a striking rise of serum transaminases was observed. When enzyme levels normalized, a reexposure using a low dose of mebendazole lead to a new more pronounced rise of transaminases suggesting a drug-induced hepatocellular damage. No measurable change of the Echinococcus cyst was observed during treatment.
D000368:Aged; D001562:Benzimidazoles / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004444:Echinococcosis, Hepatic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008463:Mebendazole / Q000009:adverse effects* / Q000627:therapeutic use; D014463:Ultrasonography
D001562:Benzimidazoles; D008463:Mebendazole
Hepatozelluläre Arzneimittelreaktion unter Mebendazoltherapie bei Echinococcus cysticus.